Natco Pharma Limited has approved the allotment of 1,70,58,082 Equity Shares as part of its Rights Issue. The shares were issued at a price of ₹750 per share, including a premium of ₹748. This allotment has increased the company’s paid-up equity share capital by ₹3.41 crore, bringing the total number of fully paid-up equity shares to over 19.61 crore.
Natco Pharma Approves Rights Issue Allotment
Natco Pharma Limited announced today, October 23, 2026, the approval of the allotment of a significant number of equity shares. This development is a continuation of the company’s previously announced Rights Issue, which aims to raise capital from eligible shareholders.
Key Allotment Details
The Fund Raising Committee of Natco Pharma, in a meeting held on October 23, 2026, considered and approved the allotment of 1,70,58,082 Equity Shares. These shares were issued at a price of ₹750 per Equity Share. This price includes a substantial premium of ₹748 per Equity Share, indicating the nominal face value of each share is ₹2.
Impact on Paid-Up Capital
Following this allotment, the paid-up equity share capital of Natco Pharma has seen a considerable increase. The total number of fully paid-up equity shares has risen from 17,91,09,870 to 19,61,67,952. Concurrently, the paid-up equity share capital has grown from approximately ₹35.82 crore to approximately ₹39.23 crore. Each equity share carries a face value of ₹2.
Meeting Details
The meeting of the Fund-Raising Committee convened at 8:30 p.m. and concluded at 8:55 p.m. on October 23, 2026.
Further information regarding this allotment is available on the company’s website at: https://files.natcopharma.co.in/investor-relations/rights-issue-2026/
Source: BSE
